
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4043595/publications.pdf Version: 2024-02-01



LEIE H RIEDMED

#	Article	IF	CITATIONS
1	Neutrophil phenotypes in bronchial airways differentiate single from dual responding allergic asthmatics. Clinical and Experimental Allergy, 2023, 53, 65-77.	2.9	5
2	Allergen provocation tests in respiratory research: building on 50â€years of experience. European Respiratory Journal, 2022, 60, 2102782.	6.7	14
3	Ciliated (FOXJ1+) Cells Display Reduced Ferritin Light Chain in the Airways of Idiopathic Pulmonary Fibrosis Patients. Cells, 2022, 11, 1031.	4.1	3
4	Eosinophilic airway diseases: basic science, clinical manifestations and future challenges. European Clinical Respiratory Journal, 2022, 9, 2040707.	1.5	5
5	Plasma proteome changes linked to late phase response after inhaled allergen challenge in asthmatics. Respiratory Research, 2022, 23, 50.	3.6	2
6	Cysteinyl–leukotriene and prostaglandin pathways in bronchial versus alveolar lavage in allergic asthmatics. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2549-2551.	5.7	0
7	Single-nucleotide polymorphisms in the sulfatase-modifying factor 1 gene are associated with lung function and COPD. ERJ Open Research, 2022, 8, 00668-2021.	2.6	2
8	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	2.9	0
9	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
10	Immune modulation via T regulatory cell enhancement: Diseaseâ€modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 90-113.	5.7	24
11	Cognitive dysfunction and quality of life during pollen season in children with seasonal allergic rhinitis. Pediatric Allergy and Immunology, 2021, 32, 67-76.	2.6	19
12	Crosstalk between Mast Cells and Lung Fibroblasts Is Modified by Alveolar Extracellular Matrix and Influences Epithelial Migration. International Journal of Molecular Sciences, 2021, 22, 506.	4.1	11
13	A new protocol for exercise testing in COPD; improved prediction algorithm for WMAX and validation of the endurance test in a placebo-controlled double bronchodilator study. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110374.	2.6	1
14	Lung Mast Cells Have a High Constitutive Expression of Carboxypeptidase A3 mRNA That Is Independent from Granule-Stored CPA3. Cells, 2021, 10, 309.	4.1	20
15	Perinatal inflammation relates to early respiratory morbidity and lung function at 12 years of age in children born very preterm. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2084-2092.	1.5	12
16	Impaired Differentiation of Chronic Obstructive Pulmonary Disease Bronchial Epithelial Cells Grown on Bronchial Scaffolds. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 201-213.	2.9	9
17	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	2.3	8
18	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-NaÃ ⁻ ve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	2.3	6

#	Article	IF	CITATIONS
19	Human Primary Airway Basal Cells Display a Continuum of Molecular Phases from Health to Disease in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 103-113.	2.9	13
20	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	2.9	4
21	ERS/EAACI statement on adherence to international adult asthma guidelines. European Respiratory Review, 2021, 30, 210132.	7.1	14
22	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.8	109
23	Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respiratory Research, 2021, 22, 279.	3.6	4
24	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	2.3	2
25	Usability of mepolizumab single-use prefilled syringe for patient self-administration. Journal of Asthma, 2020, 57, 755-764.	1.7	23
26	Pointâ€ofâ€care biomarkers in asthma management: Time to move forward. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 995-997.	5.7	13
27	Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity. Respiratory Medicine: X, 2020, 2, 100023.	1.4	31
28	Clinical and daily respiratory care and clinical trials within the COVID-19 era. European Clinical Respiratory Journal, 2020, 7, 1766817.	1.5	1
29	Reduced Variability of Endurance Time in New Protocols for Exercise Tests in COPD. International Journal of COPD, 2020, Volume 15, 3003-3012.	2.3	1
30	International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology, 2020, 20, 212.	3.1	29
31	<p>Type 2 Inflammatory Biomarker Response After Exercise Challenge Testing</p> . Journal of Asthma and Allergy, 2020, Volume 13, 269-274.	3.4	4
32	Impact of baseline COPD symptom severity on the benefit from dual <i>versus</i> mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096850.	2.6	7
33	Realâ€life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2867-2878.	5.7	45
34	Early and sustained symptom improvement with umeclidinium/vilanterol <i>versus</i> monotherapy in COPD: a <i>post hoc</i> analysis of the EMAX randomised controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092694.	2.6	4
35	A new maximal bicycle test using a prediction algorithm developed from four large COPD studies. European Clinical Respiratory Journal, 2020, 7, 1692645.	1.5	2
36	A new role for "eat me―and "don't eat me―markers on neutrophils in asthmatic airway inflammat Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1510-1512.	ion _{5.7}	3

#	Article	IF	CITATIONS
37	Fractional exhaled breath temperature in patients with asthma, chronic obstructive pulmonary disease, or systemic sclerosis compared to healthy controls. European Clinical Respiratory Journal, 2020, 7, 1747014.	1.5	9
38	VEGF synthesis and VEGF receptor 2 expression in patients with bronchiolitis obliterans syndrome after lung transplantation. Respiratory Medicine, 2020, 166, 105944.	2.9	7
39	Clinical characteristics of the BREATHE cohort – a real-life study on patients with asthma and COPD. European Clinical Respiratory Journal, 2020, 7, 1736934.	1.5	16
40	Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. European Respiratory Journal, 2020, 55, 1900110.	6.7	32
41	Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. World Allergy Organization Journal, 2020, 13, 100124.	3.5	25
42	A Randomized, Placeboâ€Controlled Trial Evaluating Effects of Lebrikizumab on Airway Eosinophilic Inflammation and Remodeling in Uncontrolled Asthma (CLAVIER). FASEB Journal, 2020, 34, 1-1.	0.5	0
43	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research, 2019, 20, 238.	3.6	81
44	Matrisome Properties of Scaffolds Direct Fibroblasts in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2019, 20, 4013.	4.1	35
45	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. European Respiratory Journal, 2019, 54, 1900900.	6.7	56
46	Enhanced local production of IL-26 in uncontrolled compared with controlled adult asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 1134-1136.e10.	2.9	7
47	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
48	Time to onset of improvements in Quality of Life from Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma. Respiratory Medicine, 2019, 147, 19-25.	2.9	4
49	Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101814.	2.6	25
50	<p>A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patients' acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)</p> . Journal of Pragmatic and Observational Research, 2019, Volume 10, 29-39.	1.5	0
51	Targeting lipid mediators in asthma. Current Opinion in Pulmonary Medicine, 2019, 25, 121-127.	2.6	15
52	The potential role of CD16 ^{high} CD62L ^{dim} neutrophils in the allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2265-2268.	5.7	10
53	EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2312-2319.	5.7	239
54	The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy, Asthma and Clinical Immunology, 2019, 15, 24.	2.0	46

#	Article	IF	CITATIONS
55	Toward clinically applicable biomarkers for asthma: An <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1835-1851.	5.7	135
56	Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force. Clinical and Translational Allergy, 2019, 9, 20.	3.2	20
57	The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clinical and Translational Allergy, 2019, 9, 21.	3.2	24
58	Expression, activity and localization of lysosomal sulfatases in Chronic Obstructive Pulmonary Disease. Scientific Reports, 2019, 9, 1991.	3.3	4
59	Oxidative Stress Attenuates TLR3 Responsiveness and Impairs Anti-viral Mechanisms in Bronchial Epithelial Cells From COPD and Asthma Patients. Frontiers in Immunology, 2019, 10, 2765.	4.8	31
60	Comparison of Normal and Metaplastic Epithelium in Patients with Stable versus Persistently Symptomatic Severe Asthma Using Laser-Capture Microdissection and Data-Independent Acquisition–Mass Spectrometry. American Journal of Pathology, 2019, 189, 2358-2365.	3.8	3
61	Effects of baseline symptom burden on treatment response in COPD. International Journal of COPD, 2019, Volume 14, 181-194.	2.3	8
62	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An <scp>EAACI</scp> Taskforce on Immunopharmacology position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 432-448.	5.7	37
63	Osteopontin protects against pneumococcal infection in a murine model of allergic airway inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 663-674.	5.7	17
64	Much ado about Biologicals: <i>Highlights of the Master Class on Biologicals, Prague, 2018</i> . Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 837-840.	5.7	2
65	Mast Cell-Mediated Orchestration of the Immune Responses in Human Allergic Asthma: Current Insights. Clinical Reviews in Allergy and Immunology, 2019, 56, 234-247.	6.5	84
66	Endoplasmic reticulum, Golgi, and lysosomes are disorganized in lung fibroblasts from chronic obstructive pulmonary disease patients. Physiological Reports, 2018, 6, e13584.	1.7	22
67	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1989-1998.e3.	3.8	44
68	Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. European Clinical Respiratory Journal, 2018, 5, 1440868.	1.5	40
69	Interferon- \hat{I}^2 deficiency at asthma exacerbation promotes MLKL mediated necroptosis. Scientific Reports, 2018, 8, 4248.	3.3	12
70	Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Journal of Proteomics, 2018, 189, 23-33.	2.4	61
71	Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. Journal of Asthma, 2018, 55, 79-88.	1.7	18
72	Club cell protein (CC16) in plasma, bronchial brushes, BAL and urine following an inhaled allergen challenge in allergic asthmatics. Biomarkers, 2018, 23, 51-60.	1.9	19

#	Article	IF	CITATIONS
73	<scp>VEGF</scp> synthesis is induced by prostacyclin and <scp>TGF</scp> â€Î² in distal lung fibroblasts from <scp>COPD</scp> patients and control subjects: <scp>I</scp> mplications for pulmonary vascular remodelling. Respirology, 2018, 23, 68-75.	2.3	29
74	Lung function after extremely preterm birth—A populationâ€based cohort study (EXPRESS). Pediatric Pulmonology, 2018, 53, 64-72.	2.0	54
75	Distal respiratory tract viral infections in young children trigger a marked increase in alveolar mast cells. ERJ Open Research, 2018, 4, 00038-2018.	2.6	8
76	The Pulmonary Extracellular Matrix Is a Bactericidal Barrier Against Haemophilus influenzae in Chronic Obstructive Pulmonary Disease (COPD): Implications for an in vivo Innate Host Defense Function of Collagen VI. Frontiers in Immunology, 2018, 9, 1988.	4.8	7
77	Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naÃ⁻ve adult volunteers. European Clinical Respiratory Journal, 2018, 5, 1529536.	1.5	6
78	Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open, 2018, 8, e022051.	1.9	3
79	Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2. Cell Communication and Signaling, 2018, 16, 59.	6.5	48
80	The neutrophil-mobilizing cytokine interleukin-26 in the airways of long-term tobacco smokers. Clinical Science, 2018, 132, 959-983.	4.3	19
81	Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. Respiratory Research, 2018, 19, 11.	3.6	22
82	The Efficiency Index (EFFi), based on volumetric capnography, may allow for simple diagnosis and grading of COPD. International Journal of COPD, 2018, Volume 13, 2033-2039.	2.3	5
83	Sex differences in asthma in swimmers and tennis players. Annals of Allergy, Asthma and Immunology, 2017, 118, 311-317.	1.0	6
84	Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler A® devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design. Pulmonary Pharmacology and Therapeutics, 2017, 44, 1-6.	2.6	3
85	Severe eosinophilic asthma: a roadmap toÂconsensus. European Respiratory Journal, 2017, 49, 1700634.	6.7	143
86	Sulfatase modifying factor 1 (SUMF1) is associated with Chronic Obstructive Pulmonary Disease. Respiratory Research, 2017, 18, 77.	3.6	9
87	Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2017, 83, 27-38.	2.8	53
88	Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets. European Clinical Respiratory Journal, 2017, 4, 1353395.	1.5	0
89	Quantitative proteomic characterization of lung-MSC and bone marrow-MSC using DIA-mass spectrometry. Scientific Reports, 2017, 7, 9316.	3.3	33
90	Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1572-1581.e3.	3.8	116

#	Article	IF	CITATIONS
91	Increased IL-17RA and IL-17RC in End-Stage COPD and the Contribution to Mast Cell Secretion of FGF-2 and VEGF. Respiratory Research, 2017, 18, 48.	3.6	19
92	Asthma referrals: a key component of asthma management that needs to be addressed. Journal of Asthma and Allergy, 2017, Volume10, 209-223.	3.4	61
93	Inflammation and chronic colonization of Haemophilus influenzae in sputum in COPD patients related to the degree of emphysema and bronchiectasis in high-resolution computed tomography. International Journal of COPD, 2017, Volume 12, 3211-3219.	2.3	22
94	Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respiratory Research, 2017, 18, 206.	3.6	5
95	Asthma symptoms, mannitol reactivity and exercise-induced bronchoconstriction in adolescent swimmers versus tennis players. Journal of Asthma and Allergy, 2017, Volume10, 249-260.	3.4	8
96	Caspase-1 deficiency reduces eosinophilia and interleukin-33 in an asthma exacerbation model. ERJ Open Research, 2017, 3, 00047-2017.	2.6	17
97	Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget, 2017, 8, 31601-31611.	1.8	25
98	Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting. European Clinical Respiratory Journal, 2016, 3, 31232.	1.5	4
99	Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Design, Development and Therapy, 2016, Volume 10, 2759-2770.	4.3	55
100	The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and luticasone propionate via Accuhaler® (ENERGITO® study). International Journal of COPD, 2016, 11, 193.	2.3	76
101	Bronchodilator response of advanced lung function parameters depending on COPD severity. International Journal of COPD, 2016, Volume 11, 2939-2950.	2.3	12
102	Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respiratory Research, 2016, 17, 73.	3.6	37
103	P062 <break></break> VEGF synthesis in distal lung fibroblasts from COPD patients and healthy control subjects; implications for pulmonary vascular remodelling. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.5	0
104	Revisiting the role of the mast cell in asthma. Current Opinion in Pulmonary Medicine, 2016, 22, 10-17.	2.6	36
105	Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels. Chest, 2016, 150, 789-798.	0.8	368
106	Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. Respiratory Medicine, 2016, 120, 54-63.	2.9	35
107	Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Scientific Reports, 2016, 6, 28698.	3.3	76
108	MSC from fetal and adult lungs possess lung-specific properties compared to bone marrow-derived MSC. Scientific Reports, 2016, 6, 29160.	3.3	43

#	Article	IF	CITATIONS
109	Acinar ventilation heterogeneity in COPD relates to diffusion capacity, resistance and reactance. Respiratory Medicine, 2016, 110, 28-33.	2.9	16
110	Exercise and asthma: an overview. European Clinical Respiratory Journal, 2015, 2, 27984.	1.5	89
111	Application of nitric oxide measurements in clinical conditions beyond asthma. European Clinical Respiratory Journal, 2015, 2, 28517.	1.5	24
112	Leukocyte infiltration patterns and structural changes in severe asthmatics with variable degree of clinical control. Clinical and Translational Allergy, 2015, 5, 07.	3.2	0
113	Small airway epithelial-C/EBPÎ ² is increased in patients with advanced COPD. Respiratory Research, 2015, 16, 133.	3.6	10
114	Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33. Journal of Translational Medicine, 2015, 13, 281.	4.4	20
115	Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA). Drug Design, Development and Therapy, 2015, 9, 753.	4.3	7
116	Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation. International Journal of COPD, 2015, 10, 881.	2.3	38
117	A new approach to assess COPD by identifying lung function break-points. International Journal of COPD, 2015, 10, 2193.	2.3	12
118	Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease. European Clinical Respiratory Journal, 2015, 2, 29445.	1.5	6
119	Versican in inflammation and tissue remodeling: The impact on lung disorders. Clycobiology, 2015, 25, 243-251.	2.5	75
120	Collagen VI Is Upregulated in COPD and Serves Both as an Adhesive Target and a Bactericidal Barrier for <i>Moraxella catarrhalis</i> . Journal of Innate Immunity, 2015, 7, 506-517.	3.8	35
121	Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD) Tj ETQq1 1	0.784314 6.7	rgBT /Overloo
122	Alveolar T-helper type-2 immunity in atopic asthma is associated with poor clinical control. Clinical Science, 2015, 128, 47-56.	4.3	21
123	IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke–induced Lymphoid Neogenesis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1232-1241.	5.6	100
124	Grading obstructive lung disease using tomographic pulmonary scintigraphy in patients with chronic obstructive pulmonary disease (COPD) and long-term smokers. Annals of Nuclear Medicine, 2015, 29, 91-99.	2.2	36
125	Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease. Advances in Therapy, 2015, 32, 809-822.	2.9	16
126	iNOS affects matrix production in distal lung fibroblasts from patients with mild asthma. Pulmonary Pharmacology and Therapeutics, 2015, 34, 64-71.	2.6	6

#	Article	IF	CITATIONS
127	TiotropiumÂ+Âolodaterol shows clinically meaningful improvements in quality of life. Respiratory Medicine, 2015, 109, 1312-1319.	2.9	144
128	The added value of hybrid ventilation/perfusion SPECT/CT in patients with stable COPD or apparently healthy smokers. Cancer-suspected CT findings in the lungs are common when hybrid imaging is used. International Journal of COPD, 2014, 10, 25.	2.3	13
129	Integrating Evidence for Managing Asthma in Patients Who Smoke. Allergy, Asthma and Immunology Research, 2014, 6, 114.	2.9	22
130	The launch of the <i>European Clinical Respiratory Journal</i> , the scientific forum of the Nordic Respiratory Journal, 2014, 1, 24949.	1.5	0
131	Primary mesenchymal stem cells in human transplanted lungs are CD90/CD105 perivascularly located tissue-resident cells. BMJ Open Respiratory Research, 2014, 1, e000027.	3.0	41
132	The role of small airway disease in asthma. Current Opinion in Pulmonary Medicine, 2014, 20, 23-30.	2.6	34
133	Exhaled Breath Temperature in Asthmatics and Controls after Eucapnic Voluntary Hyperventilation and a Methacholine Challenge Test. Respiration, 2014, 87, 149-157.	2.6	10
134	Current evidence and future research needs for FeNO measurement in respiratory diseases. Respiratory Medicine, 2014, 108, 830-841.	2.9	157
135	Oral iodinated activated charcoal improves lung function in patients with COPD. Respiratory Medicine, 2014, 108, 905-909.	2.9	1
136	Guidance on handheld inhalers in asthma and COPD guidelines. Respiratory Medicine, 2014, 108, 694-700.	2.9	32
137	Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax, 2014, 69, 130-136.	5.6	70
138	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. European Journal of Radiology, 2014, 83, 2093-2101.	2.6	30
139	The Importance of Continuity in Inhaler Device Choice for Asthma and Chronic Obstructive Pulmonary Disease. Respiration, 2014, 88, 346-352.	2.6	54
140	Controlled and uncontrolled asthma display distinct alveolar tissue matrix compositions. Respiratory Research, 2014, 15, 67.	3.6	55
141	Asthma control in patients on fixed dose combination evaluated with mannitol challenge test. Respiratory Medicine, 2014, 108, 264-270.	2.9	4
142	Pooled Safety Analysis of Once-Daily Tiotropium and Olodaterol Fixed-Dose Combination via the Respimat in Patients With Chronic Obstructive Pulmonary Disease: Two 1-Year Studies. Chest, 2014, 146, 48A.	0.8	4
143	Quality of life in children and adolescents with respiratory allergy, assessed with a generic and diseaseâ€specific instrument. Clinical Respiratory Journal, 2013, 7, 168-175.	1.6	27
144	Grass pollen allergy in children and adolescentsâ€symptoms, health related quality of life and the value of pollen prognosis. Clinical and Translational Allergy, 2013, 3, 19.	3.2	71

#	Article	IF	CITATIONS
145	Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts. Respiratory Research, 2013, 14, 21.	3.6	24
146	Inflammatory Biomarkers in Sputum Predict COPD Exacerbations. Lung, 2013, 191, 413-416.	3.3	27
147	Which Biomarkers Are Effective for Identifying Th2-Driven Inflammation in Asthma?. Current Allergy and Asthma Reports, 2013, 13, 477-486.	5.3	11
148	Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine, 2013, 107, 1709-1721.	2.9	9
149	Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respiratory Medicine, 2013, 107, 1079-1086.	2.9	53
150	Increase of club cell (Clara) protein (CC16) in plasma and urine after exercise challenge in asthmatics and healthy controls, and correlations to exhaled breath temperature and exhaled nitric oxide. Respiratory Medicine, 2013, 107, 1675-1681.	2.9	32
151	Urinary CC16 after challenge with dry air hyperpnoea and mannitol in recreational summer athletes. Respiratory Medicine, 2013, 107, 1837-1844.	2.9	11
152	Selective inhibition by simvastatin of <scp>IRF</scp> 3 phosphorylation and <scp>TSLP</scp> production in <scp>dsRNA</scp> â€challenged bronchial epithelial cells from <scp>COPD</scp> donors. British Journal of Pharmacology, 2013, 168, 363-374.	5.4	22
153	Effect of montelukast for treatment of asthma in cigarette smokers. Journal of Allergy and Clinical Immunology, 2013, 131, 763-771.e6.	2.9	58
154	Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD. Respiratory Medicine, 2013, 107, 84-90.	2.9	10
155	Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opinion on Drug Delivery, 2013, 10, 1597-1602.	5.0	31
156	Marked Epithelial Cell Pathology and Leukocyte Paucity in Persistently Symptomatic Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1475-1477.	5.6	14
157	Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β2-adrenoceptor agonist, with formoterol in patients with asthma. Therapeutic Advances in Respiratory Disease, 2013, 7, 264-271.	2.6	3
158	Flow-Volume Parameters in COPD Related to Extended Measurements of Lung Volume, Diffusion, and Resistance. Pulmonary Medicine, 2013, 2013, 1-10.	1.9	33
159	Midkine Is Part of the Antibacterial Activity Released at the Surface of Differentiated Bronchial Epithelial Cells. Journal of Innate Immunity, 2013, 5, 519-530.	3.8	16
160	Midkine Is Expressed and Differentially Processed during Chronic Obstructive Pulmonary Disease Exacerbations and Ventilator-Associated Pneumonia Associated with Staphylococcus aureus Infection. Molecular Medicine, 2013, 19, 314-323.	4.4	7
161	Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax, 2012, 67, 215-221.	5.6	66
162	ERS publications: the flagship and the fleet. European Respiratory Journal, 2012, 40, 535-537.	6.7	11

#	Article	IF	CITATIONS
163	Inhaled Corticosteroid/Long-Acting β ₂ -Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe. International Archives of Allergy and Immunology, 2012, 157, 303-310.	2.1	19
164	Exhaled Breath Temperature Increases after Exercise in Asthmatics and Controls. Respiration, 2012, 84, 283-290.	2.6	26
165	ALMA, a new tool for the management of asthma patients in clinical practice: development, validation and initial clinical findings. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 139-144.	2.3	9
166	Activation Of Double-Stranded RNA-Sensing Receptors Triggers Type I And Type III Interferon Production By Human Airway Smooth Muscle Cells. , 2012, , .		0
167	Clinical aspects of using exhaled <scp>NO</scp> in asthma diagnosis and management. Clinical Respiratory Journal, 2012, 6, 193-207.	1.6	33
168	Extended diagnostic criteria used for indirect challenge testing in elite asthmatic swimmers. Respiratory Medicine, 2012, 106, 15-24.	2.9	14
169	Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNÎ ² production in diseased bronchial epithelial cells. International Immunopharmacology, 2012, 13, 292-300.	3.8	11
170	Glycoproteomic identification of galectin-3 and -8 ligands in bronchoalveolar lavage of mild asthmatics and healthy subjects. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1429-1436.	2.4	19
171	Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients. Journal of Translational Medicine, 2012, 10, 171.	4.4	26
172	Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation, 2012, 32, 147-155.	2.2	7
173	Asthma endotypes: AÂnew approach to classification of disease entities within the asthma syndrome. Journal of Allergy and Clinical Immunology, 2011, 127, 355-360.	2.9	1,007
174	Mast cell–associated alveolar inflammation in patients with atopic uncontrolled asthma. Journal of Allergy and Clinical Immunology, 2011, 127, 905-912.e7.	2.9	96
175	Fibroblast phenotypes and their activity are changed in the wound healing process after lung transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 945-54.	0.6	19
176	Leukotriene receptors are differently expressed in fibroblast from peripheral versus central airways in asthmatics and healthy controls. Prostaglandins Leukotrienes and Essential Fatty Acids, 2011, 85, 67-73.	2.2	22
177	dsRNA-induced expression of thymic stromal lymphopoietin (TSLP) in asthmatic epithelial cells is inhibited by a small airway relaxant. Pulmonary Pharmacology and Therapeutics, 2011, 24, 59-66.	2.6	38
178	Exercise but not mannitol provocation increases urinary Clara cell protein (CC16) in elite swimmers. Respiratory Medicine, 2011, 105, 31-36.	2.9	64
179	TGFβ-induced matrix production by bronchial fibroblasts in asthma: Budesonide and formoterol effects. Respiratory Medicine, 2011, 105, 1296-1307.	2.9	24
180	Comparison of central and peripheral airway involvement before and during methacholine, mannitol and eucapnic hyperventilation challenges in mild asthmatics. Clinical Respiratory Journal, 2011, 5, 10-18.	1.6	22

#	Article	IF	CITATIONS
181	Targeting small airways, a step further in asthma management. Clinical Respiratory Journal, 2011, 5, 131-135.	1.6	9
182	Immune remodelling in peripheral lungs of COPD patients. Clinical Respiratory Journal, 2011, 5, 7-7.	1.6	0
183	Swedish translation and validation of the Pediatric Allergic Disease Quality of Life Questionnaire (PADQLQ). Acta Paediatrica, International Journal of Paediatrics, 2011, 100, 242-247.	1.5	10
184	Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respiratory Research, 2011, 12, 139.	3.6	72
185	Fibrocytes and the tissue niche in lung repair. Respiratory Research, 2011, 12, 76.	3.6	45
186	Efficient induction of functional neurons from adult human fibroblasts. Cell Cycle, 2011, 10, 3311-3316.	2.6	69
187	IL-9 Governs Allergen-induced Mast Cell Numbers in the Lung and Chronic Remodeling of the Airways. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 865-875.	5.6	187
188	Hyperpnea-Induced Bronchoconstriction and Urinary CC16 Levels in Athletes. Medicine and Science in Sports and Exercise, 2011, 43, 1207-1213.	0.4	45
189	Altered fibroblast proteoglycan production in COPD. Respiratory Research, 2010, 11, 55.	3.6	86
190	Levels of cysteinylâ€leukotrienes in exhaled breath condensate are not due to saliva contamination. Clinical Respiratory Journal, 2010, 4, 83-88.	1.6	10
191	Pathological airway remodelling in inflammation. Clinical Respiratory Journal, 2010, 4, 1-8.	1.6	64
192	Altered matrix production in the distal airways of individuals with asthma. Thorax, 2010, 65, 670-676.	5.6	65
193	Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology, 2010, 49, 2322-2326.	1.9	26
194	Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers. British Journal of Sports Medicine, 2010, 44, 827-832.	6.7	58
195	Alterations in Lung Mast Cell Populations in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 206-217.	5.6	104
196	MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. Journal of Allergy and Clinical Immunology, 2010, 125, 1344-1353.e2.	2.9	481
197	Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respiratory Medicine, 2010, 104, 1297-1303.	2.9	49
198	Relationship between matrix production by bronchial fibroblasts and lung function and AHR in asthma. Respiratory Medicine, 2010, 104, 1799-1808.	2.9	21

#	Article	IF	CITATIONS
199	Disease activity in asthma, more than symptom control and more than eosinophilic inflammation. Clinical Respiratory Journal, 2009, 3, 187-188.	1.6	1
200	Clinical commentary – COPD is not a systemic disease. Respiratory Medicine, 2009, 103, 1270-1275.	2.9	1
201	Fibrocytes are associated with vascular and parenchymal remodelling in patients with obliterative bronchiolitis. Respiratory Research, 2009, 10, 103.	3.6	35
202	Montelukast in the treatment of asthma and beyond. Expert Review of Clinical Immunology, 2009, 5, 639-658.	3.0	48
203	Complementary therapy in asthma: inhaled corticosteroids and what?. Current Opinion in Pulmonary Medicine, 2009, 15, 46-51.	2.6	6
204	Allergic rhinitis with hyper-responsiveness differ from asthma in degree of peripheral obstruction during metacholine challenge test. Clinical Physiology and Functional Imaging, 2008, 28, 81-85.	1.2	24
205	Allergy: a systemic disease? The HUNT and Young–HUNT study, Norway Pediatric Allergy and Immunology, 2008, 19, 730-736.	2.6	12
206	Methods used in clinical development of novel anti-asthma therapies. Respiratory Medicine, 2008, 102, 332-338.	2.9	8
207	Achieving asthma control in practice: Understanding the reasons for poor control. Respiratory Medicine, 2008, 102, 1681-1693.	2.9	199
208	Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits. Therapeutic Advances in Respiratory Disease, 2008, 2, 149-161.	2.6	8
209	Female gender is associated with higher incidence and more stable respiratory symptoms during adolescence. Respiratory Medicine, 2007, 101, 896-902.	2.9	53
210	Effect of inhaled corticosteroids on forearm bone mineral density: The HUNT Study, Norway. Respiratory Medicine, 2007, 101, 1744-1752.	2.9	16
211	Peripheral nitric oxide is increased in rhinitic patients with asthma compared to bronchial hyperresponsiveness. Respiratory Medicine, 2007, 101, 2321-2326.	2.9	30
212	Adolescents with wheeze have increased risk of additional health problems. The Young–HUNT study, Norway. Preventive Medicine, 2007, 44, 178-182.	3.4	4
213	Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation. Journal of Allergy and Clinical Immunology, 2007, 120, 1269-1275.	2.9	75
214	Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respiratory Research, 2006, 7, 11.	3.6	44
215	Tissue fibrocytes in patients with mild asthma: A possible link to thickness of reticular basement membrane?. Respiratory Research, 2006, 7, 50.	3.6	122
216	Specific Haptoglobin Expression in Bronchoalveolar Lavage during Differentiation of Circulating Fibroblast Progenitor Cells in Mild Asthma. Journal of Proteome Research, 2006, 5, 1479-1483.	3.7	39

#	Article	IF	CITATIONS
217	Methodological improvements for measuring eicosanoids and cytokines in exhaled breath condensate. Respiratory Medicine, 2006, 100, 34-38.	2.9	62
218	Adolescent respiratory symptoms—girls are at risk: The Young-HUNT study, Norway. Respiratory Medicine, 2006, 100, 471-476.	2.9	24
219	Evidence-based recommendations or "Show me the patients selected and I will tell you the resultsâ€. Respiratory Medicine, 2006, 100, S17-S21.	2.9	6
220	Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma:an efficacy and cost-effectiveness study. Current Medical Research and Opinion, 2006, 22, 809-821.	1.9	59
221	Montelukast in the treatment of asthma as a systemic disease. Expert Review of Clinical Immunology, 2005, 1, 325-336.	3.0	8
222	How representative are clinical study patients with asthma or COPD for a larger "real life― population of patients with obstructive lung disease?. Respiratory Medicine, 2005, 99, 11-19.	2.9	324
223	Presence of Activated Mobile Fibroblasts in Bronchoalveolar Lavage from Patients with Mild Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1049-1056.	5.6	50
224	Use of inhaled corticosteroids and bone mineral density in a population based study: the Nord-TrÃ,ndelag Health Study(the HUNT Study). Pharmacoepidemiology and Drug Safety, 2004, 13, 569-579.	1.9	25
225	Current and Emerging Nonsteroidal Anti-Inflammatory Therapies Targeting Specific Mechanisms in Asthma and Allergy. Treatments in Respiratory Medicine, 2004, 3, 235-246.	1.4	20
226	Effects of Montelukast and Salmeterol on Physical Performance and Exercise Economy in Adult Asthmatics With Exercise-Induced Bronchoconstriction. Chest, 2004, 126, 1154-1160.	0.8	25
227	Dysregulated secretoglobin expression in human lung cancers. Lung Cancer, 2003, 41, 49-56.	2.0	31
228	Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. Journal of Allergy and Clinical Immunology, 2003, 112, 72-78.	2.9	79
229	Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ: British Medical Journal, 2003, 327, 891-0.	2.3	190
230	Bronchial Mast Cells Are the Dominating LTC ₄ S-Expressing Cells in Aspirin-Tolerant Asthma. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 683-693.	2.9	46
231	Perfusion abnormalities in pulmonary embolism studied with perfusion MRI and ventilation-perfusion scintigraphy: An intra-modality and inter-modality agreement study. Journal of Magnetic Resonance Imaging, 2002, 15, 386-394.	3.4	60
232	A study of the association between exercise-induced wheeze and exercise versus methacholine-induced bronchoconstriction in adolescents. Pediatric Allergy and Immunology, 2002, 13, 203-208.	2.6	21
233	Cellular and noncellular components of bronchoalveolar lavage fluid in HIVâ€1â€infected children with radiological evidence of interstitial lung damage. Pediatric Pulmonology, 2001, 31, 205-213.	2.0	10
234	Placebo-Controlled Study of Inhaled Budesonide on Indices of Airway Inflammation in Bronchoalveolar Lavage Fluid and Bronchial Biopsies in Cross-Country Skiers. Respiration, 2000, 67, 417-425.	2.6	93

#	Article	IF	CITATIONS
235	Effects of tobacco smoke on tumor growth and radiation response of Dunning R3327 prostate adenocarcinoma in rats. , 2000, 42, 253-259.		6
236	Perfusion magnetic resonance imaging of the lung: Characterization of pneumonia and chronic obstructive pulmonary disease. A feasibility study. Journal of Magnetic Resonance Imaging, 2000, 12, 224-231.	3.4	43
237	Evidence of Airway Inflammation and Remodeling in Ski Athletes with and without Bronchial Hyperresponsiveness to Methacholine. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 2086-2091.	5.6	299
238	Adolescent Occasional Smokers, a Target Group for Smoking Cessation? The Nord–TrÃ,ndelag Health Study, Norway, 1995–1997. Preventive Medicine, 2000, 31, 682-690.	3.4	33
239	Nordic consensus report on asthma management. Respiratory Medicine, 2000, 94, 299-327.	2.9	46
240	Effects of tobacco smoke on tumor growth and radiation response of Dunning R3327 prostate adenocarcinoma in rats. Prostate, 2000, 42, 253.	2.3	1
241	A Closed-Chest Pulmonary Artery Occlusion/Reperfusion Model in the Pig. Investigative Radiology, 2000, 35, 295-303.	6.2	16
242	Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiotherapy and Oncology, 1998, 49, 41-47.	0.6	96
243	Lymphoid Aggregates in Endobronchial Biopsies from Young Elite Cross-country Skiers. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 597-601.	5.6	101
244	Effects of Breathing Cold and Warm Air on Lung Function and Physical Performance in Asthmatic and Nonasthmatic Athletes during Exercise in the Cold. Annals of the New York Academy of Sciences, 1997, 813, 751-756.	3.8	18
245	Upregulation of gap junction protein connexin43 in alveolar epithelial cells of rats with radiation-induced pulmonary fibrosis. Histochemistry and Cell Biology, 1996, 106, 419-424.	1.7	8
246	Experimental Evaluation of the Effect of Filtration of Diesel Exhaust by Biologic Exposure Indicators. American Journal of Industrial Medicine, 1995, 27, 91-106.	2.1	14
247	Sephadexâ€induced granulomatous alveolitis in rat: Effects of antigen manipulation. American Journal of Industrial Medicine, 1994, 25, 73-78.	2.1	10
248	Lipopolysaccharide (LPS) inhalation in healthy subjects causes bronchoalveolar neutrophilia, lymphocytosis, and fibronectin increase. American Journal of Industrial Medicine, 1994, 25, 103-104.	2.1	28
249	Interleukin-2-administration intravenously and intrapleurally in a patient with primary pulmonary adenocarcinoma. Cellular responses in peripheral blood, intrapleural fluid and bronchoalveolar lavage. Biotherapy (Dordrecht, Netherlands), 1993, 6, 1-7.	0.7	5
250	Local Host Response in the Lower Respiratory Tract in Nephropathia Epidemica. Scandinavian Journal of Infectious Diseases, 1993, 25, 639-646.	1.5	25
251	Mast Cells and Biogenic Amines in Radiation-induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 112-117.	2.9	49
252	Hyaluronic Acid (Hyaluronan) in BAL Fluid Distinguishes Farmers with Allergic Alveolitis from Farmers with Asymptomatic Alveolitis. Chest, 1992, 101, 109-114.	0.8	37

#	Article	IF	CITATIONS
253	Bronchoalveolar lavage in persons acutely exposed to dust in the farm environment. American Journal of Industrial Medicine, 1990, 17, 106-106.	2.1	3
254	The role of sex and age in yeast cell phagocytosis by monocytes from healthy blood donors. Mechanisms of Ageing and Development, 1990, 51, 55-61.	4.6	13
255	The Eosinophil Component of the Alveolitis in Idiopathic Pulmonary Fibrosis: Signs of Eosinophil Activation in the Lung Are Related to Impaired Lung Function. The American Review of Respiratory Disease, 1989, 139, 373-377.	2.9	114
256	Does Smoking Protect Against Radiation-induced Pneumonitis?. International Journal of Radiation Biology, 1989, 56, 721-724.	1.8	13
257	Estramustine inhibits monocyte phagocytosis. Prostate, 1988, 13, 49-55.	2.3	23
258	Bronchoalveolar Mastocytosis in Farmer's Lung Is Related to the Disease Activity. Archives of Internal Medicine, 1988, 148, 1362.	3.8	36
259	The Mast Cell and Signs of Pulmonary Fibroblast Activation in Sarcoidosis. International Archives of Allergy and Immunology, 1987, 82, 298-301.	2.1	37
260	Nutritional Status of Medical Patients on Emergency Admission to Hospital. Acta Medica Scandinavica, 1982, 212, 151-156.	0.0	36